{"url":"https://lda.senate.gov/api/v1/filings/d2530ae0-1069-40c3-bf80-e9979b5a7e5b/","filing_uuid":"d2530ae0-1069-40c3-bf80-e9979b5a7e5b","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/d2530ae0-1069-40c3-bf80-e9979b5a7e5b/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"John McManus","dt_posted":"2026-07-20T12:29:57-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"610 10th St NW","registrant_address_2":"#300","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":286096,"url":"https://lda.senate.gov/api/v1/registrants/286096/","house_registrant_id":36969,"name":"THE MCMANUS GROUP","description":"Consulting","address_1":"610 10th St. NW","address_2":"Suite 300","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JORDAN OPDAHL","contact_telephone":"+1 301-775-7048","dt_updated":"2026-07-20T15:27:02.288049-04:00"},"client":{"id":176429,"url":"https://lda.senate.gov/api/v1/clients/176429/","client_id":12,"name":"PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA","general_description":"Represents the leading research-based pharmaceutical companies in the US.","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-02-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":9573,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MCMANUS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140472,"prefix":null,"prefix_display":null,"first_name":"ALEX","nickname":null,"middle_name":null,"last_name":"WHALEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":9573,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MCMANUS","suffix":null,"suffix_display":null},"covered_position":"Staff Director W&M Health Subcommittee; LA, Rep. Bill Thomas","new":false},{"lobbyist":{"id":140472,"prefix":null,"prefix_display":null,"first_name":"ALEX","nickname":null,"middle_name":null,"last_name":"WHALEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":9573,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MCMANUS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140472,"prefix":null,"prefix_display":null,"first_name":"ALEX","nickname":null,"middle_name":null,"last_name":"WHALEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}